Cellectar Biosciences, Inc. (CLRB) Posts 79% Major Response in WM Subset
Cellectar Biosciences reported a 79.2% major response rate, 87.5% overall response, and duration exceeding 16 months in a Phase 2 CLOVER WaM subset treated immediately post-BTKi, and plans a Phase 3 confirmatory trial with an accelerated approval filing targeted for 1H27.Material DetailsContext by…